COVID-19 Drug Associated APIs Global Market Report 2024

Request Free Sample Buy Report

Global COVID-19 Drug Associated APIs Market Report 2024

COVID-19 Drug Associated APIs Global Market Report 2024 – By Drug Class (Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class), By Synthesis Type (Synthetic, Biotech), By Business Mode (Captive API, Merchant API) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request Sample

Request For Discount

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

COVID-19 Drug Associated APIs Market Definition And Segments

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called active pharmaceutical components serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body.

The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs, or simply antimalarials, are antiparasitic chemical agents that can be used to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, and branded, and involve various modes of business such as captive API and merchant API.

The COVID-19 associated APIs market covered in this report is segmented –

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Classes

2) By Synthesis Type: Synthetic, Biotech

3) By Business Mode: Captive API, Merchant API

The COVID-19 drug-associated APIs market size has grown strongly in recent years. It will grow from $6.37 billion in 2023 to $6.75 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the rising prevalence of COVID-19, increasing awareness of COVID-19 treatment options, expanding access to COVID-19 drugs, growing demand for COVID-19 drugs for prophylaxis, government initiatives, and supply chain resilience.

The COVID-19 drug-associated APIs market size is expected to see strongly grown in the next few years. It will grow to $8.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the development of new COVID-19 drug modalities, increasing clinical trials for COVID-19 drugs, rising demand for COVID-19 vaccines, emerging variants, vaccination campaigns, and pandemic preparedness. Major trends in the forecast period include customized API production, diversification of API sources, advanced manufacturing technologies, digitalization and data analytics, sustainability and green chemistry.

Elevated Demand For Active Pharmaceutical Ingredients (APIS) Driven By Antivirals, Antimalarials, And Respiratory Medications In The COVID-19 Drug Market

High demand for antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active components used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID-19 patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19 drug-associated APIs market over the forecast period.

Government Initiatives Catalysts For Growth In The COVID-19 Drug-Associated API Market

Government initiatives for research and development in healthcare are expected to propel the growth of the COVID-19 drug-associated API market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Government initiatives play a pivotal role in creating an enabling environment for the development, production, and distribution of COVID-19 drug-associated APIs. For instance, in 2022, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced £260 million ($270.65) million in funding to boost healthcare research and manufacturing. This was committed by BEIS and DHSC to support NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) to help expand life sciences manufacturing in the UK. Therefore, government initiatives for research and development in healthcare are driving the growth of the COVID-19 drug-associated API market.

Major companies operating in the COVID-19 drug associated APIs market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

Supply Chain Disruptions In The COVID-19 Drug-Associated APIs Market

The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% of generic APIs used in the USA. The restrictions imposed on the export of pharmaceutical products owing to COVID-19 supply chain disruptions restricted market growth. For instance, in June 2021, according to the United Nations Conference on Trade and Development, a US-based intergovernmental organization, during the initial phases of the epidemic, over 80 nations implemented bans on the export of medical and personal protective equipment, resulting in significant disruptions to the supply chain. Remarkably, nearly 60% of these restrictions remain in force today. The ban was imposed due to API and other bulk drug supply chain disruptions caused by restrictive measures such as lockdowns and factory closures in many countries around the world to ensure disease containment. Thus, shortages caused by disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months.

Pharmaceutical Industry's Strategic Expansion In API Production To Meet Surging Demand For COVID-19 Drugs

Key players operating in the pharmaceutical industry that manufacture COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of COVID-19 cases across the globe. For instance, in October 2023, Merck & Co., Inc., a US-based pharmaceutical company, with a recent partnership with the Heavy Water Board in India, hopes to tap into the deuterated raw compound industry, which is presently worth around $100 million and has the potential to rise to $1 billion over the next five to ten years. Merck seeks to support India's chemical, pharmaceutical, and technical sectors by offering high-quality compounds for the manufacture of medicines, semiconductors, OLEDs, and electronics. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

Innovative Strategies In The COVID-19 Drug-Associated APIs Market Focus On Oral Treatments

Major companies operating in the COVID-19 drug-associated APIs market are increasing their focus on introducing innovative products, such as oral treatment for COVID-19, to gain a competitive edge in the market. Oral treatment for COVID-19 refers to medications that are taken by mouth (orally) to manage and treat the infection caused by the SARS-CoV-2 virus, which is responsible for COVID-19. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID, which was approved by the FDA. The oral investigational drug, a SARS-CoV-2 protease inhibitor, has shown an 89% reduction in hospitalization or death risk compared to a placebo in high-risk, non-hospitalized adults with COVID-19. Designed for early administration, it aims to be prescribed at the first sign of infection or exposure awareness, potentially preventing severe illness, hospitalization, and death.

Sterling Pharma Solutions Acquires API Manufacturing Facility From Novartis

In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, acquired an active pharmaceutical ingredient (API) manufacturing facility from Novartis for an undisclosed sum. With this acquisition, Sterling's expanding API manufacturing capabilities, as well as the deal's ongoing supply arrangement with Novartis, are going to keep manufacturing several APIs for cardiovascular, immunology, and oncology medications. Novartis AG is a US-based pharmaceutical company that manufactures active pharmaceutical ingredients (API).

North America was the largest region in the COVID-19 drug-associated APIs market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated APIs market share during the forecast period. The regions covered in the COVID-19 drug associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the COVID-19 drug associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

COVID-19 Drug Associated APIs Market Report Scope

Report Attribute	Details
Market Size Value In 2024	$6.75 billion
Revenue Forecast In 2033	$8.52 billion
Growth Rate	CAGR of 6% from 2024 to 2033
Base Year For Estimation	2023
Actual Estimates/Historical Data	2018-2023
Forecast Period	2024 - 2028 - 2033
Market Representation	Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered	1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class 2) By Synthesis Type: Synthetic, Biotech 3) By Business Mode: Captive API, Merchant API
Regional Scope	Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope	Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled	Dr. Reddy's Laboratories Ltd.; Lianyungang Guike Pharmaceutical CO. LTD.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Sandoz Srl; Lupin Limited; Aurobindo Pharma Ltd.; Shanghai Shyndec Pharmaceutical Co. Ltd.; Zhejiang Yatai Pharmaceutical Co. Ltd.; Zhejiang Guobang Pharmaceutical Co Ltd.; Cipla Limited; Shandong Boyuan Pharmaceutical Co. Ltd.; Aspiro Pharma Ltd.; Qilu Antibiotics Pharmaceutical Co. Ltd.; Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd.; Zhejiang Cheng Yi Pharmaceutical; Star Lake Bioscience Co.Inc.; Hetero Labs Ltd.; Geno Pharmaceuticals Ltd.; Mylan Laboratories Ltd.; Ipca Laboratories Limited; Zydus Takeda Healthcare Private Limited; Mangalam Drugs & Organics; Wallace Pharmaceuticals; Zhejiang Hisun Pharmaceutical Co. Ltd.; Zhejiang Huahai Pharmaceutical Co. Ltd.; Zhejiang Jiuzhou Pharmaceutical Co. Ltd.; Zhejiang NHU Co. Ltd.; Zhejiang Xianju Pharmaceutical Co. Ltd.; Zhejiang Yongtai Technology Co. Ltd.; Zhejiang Zhebei Pharmaceutical Co. Ltd.; Zhejiang Tianyu Pharmaceutical Co. Ltd.; Zhejiang Aisheng Pharmaceutical Co. Ltd.; Zhejiang Aokang Pharmaceutical Co. Ltd.; Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

Table Of Contents

1. Executive Summary

2. COVID-19 Drug Associated APIs Market Characteristics

3. COVID-19 Drug Associated APIs Market Trends And Strategies

4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market

4.2. Ukraine-Russia War Impact On the Market

4.3. COVID-19 Impact On the Market

5. Global COVID-19 Drug Associated APIs Market Size and Growth

5.1. Global COVID-19 Drug Associated APIs Market Drivers and Restraints

5.1.1. Drivers Of The Market

5.1.2. Restraints Of The Market

5.2. Global COVID-19 Drug Associated APIs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

5.3. Global COVID-19 Drug Associated APIs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. COVID-19 Drug Associated APIs Market Segmentation

6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Antimalarials

Bronchodilators

Antibiotics

Antivirals

Other Drug Class

6.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Synthetic

Biotech

6.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Captive API

Merchant API

7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific COVID-19 Drug Associated APIs Market

8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.3. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.4. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China COVID-19 Drug Associated APIs Market

9.1. China COVID-19 Drug Associated APIs Market Overview

9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.3. China COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.4. China COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India COVID-19 Drug Associated APIs Market

10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.2. India COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.3. India COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan COVID-19 Drug Associated APIs Market

11.1. Japan COVID-19 Drug Associated APIs Market Overview

11.2. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.3. Japan COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.4. Japan COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia COVID-19 Drug Associated APIs Market

12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.2. Australia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.3. Australia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia COVID-19 Drug Associated APIs Market

13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.2. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.3. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea COVID-19 Drug Associated APIs Market

14.1. South Korea COVID-19 Drug Associated APIs Market Overview

14.2. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.3. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.4. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe COVID-19 Drug Associated APIs Market

15.1. Western Europe COVID-19 Drug Associated APIs Market Overview

15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.3. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.4. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK COVID-19 Drug Associated APIs Market

16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.2. UK COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.3. UK COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany COVID-19 Drug Associated APIs Market

17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.2. Germany COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.3. Germany COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France COVID-19 Drug Associated APIs Market

18.5. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.6. France COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.7. France COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy COVID-19 Drug Associated APIs Market

19.9. Italy COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.10. Italy COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.11. Italy COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain COVID-19 Drug Associated APIs Market

20.13. Spain COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.14. Spain COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.15. Spain COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe COVID-19 Drug Associated APIs Market

21.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview

21.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.3. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.4. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia COVID-19 Drug Associated APIs Market

22.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.2. Russia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.3. Russia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America COVID-19 Drug Associated APIs Market

23.1. North America COVID-19 Drug Associated APIs Market Overview

23.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.3. North America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.4. North America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA COVID-19 Drug Associated APIs Market

24.1. USA COVID-19 Drug Associated APIs Market Overview

24.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.3. USA COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.4. USA COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada COVID-19 Drug Associated APIs Market

25.1. Canada COVID-19 Drug Associated APIs Market Overview

25.2. Canada COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.3. Canada COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.4. Canada COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America COVID-19 Drug Associated APIs Market

26.1. South America COVID-19 Drug Associated APIs Market Overview

26.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.3. South America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.4. South America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil COVID-19 Drug Associated APIs Market

27.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.2. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.3. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East COVID-19 Drug Associated APIs Market

28.1. Middle East COVID-19 Drug Associated APIs Market Overview

28.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.3. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.4. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa COVID-19 Drug Associated APIs Market

29.1. Africa COVID-19 Drug Associated APIs Market Overview

29.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.3. Africa COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.4. Africa COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

30.1. COVID-19 Drug Associated APIs Market Competitive Landscape

30.2. COVID-19 Drug Associated APIs Market Company Profiles

30.2.1. Dr. Reddy's Laboratories Ltd.

30.2.1.1. Overview

30.2.1.2. Products and Services

30.2.1.3. Strategy

30.2.1.4. Financial Performance

30.2.2. Lianyungang Guile Pharmaceutical CO. LTD.

30.2.2.1. Overview

30.2.2.2. Products and Services

30.2.2.3. Strategy

30.2.2.4. Financial Performance

30.2.3. Alembic Pharmaceuticals Ltd.

30.2.3.1. Overview

30.2.3.2. Products and Services

30.2.3.3. Strategy

30.2.3.4. Financial Performance

30.2.4. Wockhardt Ltd.

30.2.4.1. Overview

30.2.4.2. Products and Services

30.2.4.3. Strategy

30.2.4.4. Financial Performance

30.2.5. Sandoz Srl

30.2.5.1. Overview

30.2.5.2. Products and Services

30.2.5.3. Strategy

30.2.5.4. Financial Performance

31. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking

32. Global COVID-19 Drug Associated APIs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

34. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis

34.1 COVID-19 Drug Associated APIs Market In 2028 - Countries Offering Most New Opportunities

34.2 COVID-19 Drug Associated APIs Market In 2028 - Segments Offering Most New Opportunities

34.3 COVID-19 Drug Associated APIs Market In 2028 - Growth Strategies

34.3.1 Market Trend Based Strategies

34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations

35.2. Currencies

35.3. Historic And Forecast Inflation Rates

35.4. Research Inquiries

35.5. The Business Research Company

35.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 6: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 7: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 8: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 9: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 10: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 11: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 12: China, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 13: China, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 14: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 15: India, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 16: India, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 17: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 18: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 19: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 20: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 21: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 22: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 23: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 24: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 25: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 26: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 27: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 28: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 29: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 30: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 31: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 32: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 33: UK, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 34: UK, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 35: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 36: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 37: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 38: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 39: France, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 40: France, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 41: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 42: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 43: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 44: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 45: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 46: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 47: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 48: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 49: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 50: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 51: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 52: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 53: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 54: North America, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 55: North America, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 56: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 57: USA, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 58: USA, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 59: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 60: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 61: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 62: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 63: South America, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 64: South America, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 65: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 66: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 67: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 68: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 69: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 70: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 71: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 72: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 73: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 74: Dr. Reddy's Laboratories Ltd. Financial Performance

Table 75: Lianyungang Guile Pharmaceutical CO. LTD. Financial Performance

Table 76: Alembic Pharmaceuticals Ltd. Financial Performance

Table 77: Wockhardt Ltd. Financial Performance

Table 78: Sandoz Srl Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2018-2023, $ Billion

Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Figure 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 4: Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 5: Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 6: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 7: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 8: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 9: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 10: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 11: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 12: China, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 13: China, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 14: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 15: India, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 16: India, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 17: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 18: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 19: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 20: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 21: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 22: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 23: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 24: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 25: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 26: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 27: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 28: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 29: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 30: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 31: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 32: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 33: UK, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 34: UK, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 35: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 36: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 37: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 38: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 39: France, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 40: France, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 41: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 42: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 43: Italy, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 44: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 45: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 46: Spain, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 47: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 48: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 49: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 50: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 51: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 52: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 53: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 54: North America, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 55: North America, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 56: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 57: USA, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 58: USA, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 59: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 60: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 61: Canada, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 62: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 63: South America, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 64: South America, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 65: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 66: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 67: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 68: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 69: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 70: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 71: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 72: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 73: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 74: Dr. Reddy's Laboratories Ltd. Financial Performance

Figure 75: Lianyungang Guile Pharmaceutical CO. LTD. Financial Performance

Figure 76: Alembic Pharmaceuticals Ltd. Financial Performance

Figure 77: Wockhardt Ltd. Financial Performance

Figure 78: Sandoz Srl Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth

COVID-19 Rapid Test Kits Market 2022 – By Test Type (RT PCR Test, Rapid Antigen Test, Rapid Antibody Test, Others), By Test Components (PCR Machines, Equipment And Extraction Kits, Reagents), By Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Blood, Others), By End-Users (Hospitals And Clinics, Diagnostic Laboratories, Home Care, Others), And By Region, Opportunities And Strategies – Global Forecast To 2031

View Report

COVID-19 Rapid Test Kits Global Market Report 2024 – By Test Type (RT PCR Test, Rapid Antigen Test, Rapid Antibody Test, Others), By Test Components (PCR Machines, Equipment And Extraction Kits, Reagents), By Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Blood, Others), By End-Users (Hospitals And Clinics, Diagnostic Laboratories, Home Care, Others) – Market Size, Trends, And Global Forecast 2024-2025

View Report

DTP Vaccines Global Market Report 2024 – By Product type (DTaP, TD, Tdap), By Disease (Diphtheria, Pertussis, Tetanus), By End-User (Hospitals, Clinics, Vaccination Centers) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biologics Global Market Report 2024 – By Type (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), By Drug Classification (Branded Drugs, Generic Drugs), By Route Of Administration (Oral, Other Route Of Administration), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033

View Report

COVID-19 (COVID-19) Current Therapy Global Market Report 2024 – By Drug Type (Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others), By Route Of Administration (Oral, Intravenous), By End-User (Hospitals, Clinics, Home Care, Others) – Market Size, Trends, And Global Forecast 2024-2035

View Report

Hydroxychloroquine Global Market Report 2024 – By Drug Activity (Anti-Malarial Drug, Anti-Rheumatic Drug, Lupus Suppressant Drug, Anti COVID-19 Drug, Other Drug Activity), By Formulation (Tablets, Injection), By Application (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, COVID-19, Other Applications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Stores, Retail Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

COVID-19 Detection Test Kits and Consumables Global Market Report 2024 – By Kits (Viral Load Testing Kits (qPCR and RT-PCR), Virus Neutralizing Assay Kits, Antibody Detection Kits (Elisa), Viral Antigen Detection Test Kits, Other Kits), By Consumables (Swabs, Tubes, Viral Transfer Media, Reagents, Other Consumables), By Specimen Type (Nose & Throat Swab, Blood, Sputum, Nasal Aspirate), By End Use (Hospitals, Clinics, Public Health Labs, Private And Commercial Labs, Physicians Labs, Research Institutes, Other End Uses) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Pediatric Vaccine Market 2021 - By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Toxoid, Conjugate), By Application (Infectious Disease, Allergy, Cancer) And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the COVID-19 drug associated APIs market?

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called "active pharmaceutical components" serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body. For further insights on the COVID-19 drug associated APIs market, request a sample here

How will the COVID-19 drug associated APIs market drivers and restraints affect the COVID-19 drug associated APIs market dynamics? What forces will shape the COVID-19 drug associated APIs industry going forward?

The COVID-19 drug associated APIs market growth is aided by high demand for some antiretrovirals, antimalarials, sedatives, bronchodilators and other respiratory drugs. However, some COVID-19 drug associated APIs market restraints include disruptions caused by the COVID-19 outbreak in the supply chain of medical products. For further insights on the COVID-19 drug associated APIs market, request a sample here

What is the forecast market size or the forecast market value of the COVID-19 drug associated APIs market?

The COVID-19 drug associated APIs market is expected to reach $8.02 billion in 2027 at a rate of 5.9%. For further insights on the COVID-19 drug associated APIs market, request a sample here

How is the COVID-19 drug associated APIs market segmented?

The global COVID-19 drug associated APIs market is segmented as
1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class
2) By Synthesis Type: Synthetic, Biotech
3) By Business Mode: Captive API, Merchant API
For further insights on the COVID-19 drug associated APIs market, request a sample here

Which region has the largest share of the COVID-19 drug associated APIs market? What are the largest region's market size and growth rate?

North America was the largest region in the COVID-19 drug associated APIs market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the COVID-19 drug associated APIs market?

Key competitors in the COVID-19 drug associated APIs market are, Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd, Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co Ltd, Yatai Pharma, Zhejiang Guobang Pharmaceutical Co Ltd., Cipla, Shandong Boyuan Pharmaceutical, Aspiro Pharma, Qilu Antibiotics Pharmaceutical Co Ltd, Shenzhen China Resources Gosun Pharmaceutical Co Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co Inc., Hetero Labs, Geno Pharmaceuticals, Mylan Laboratories, IPCA Labs, Zydus Takeda, Mangalam Drugs & Organics, Wallace Pharma. For further insights on the COVID-19 drug associated APIs market, request a sample here.

What are the key trends in the COVID-19 drug associated APIs market?

Major trends influencing the COVID-19 drug associated APIs market include focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For further insights on the COVID-19 drug associated APIs market, request a sample here.

What are the major opportunities in the COVID-19 drug associated APIs market? What are the strategies for the COVID-19 drug associated APIs market?

For detailed insights on the major opportunities and strategies in the COVID-19 drug associated APIs market, request a sample here.

How does the COVID-19 drug associated APIs market relate to the overall economy and other similar markets?

For detailed insights on COVID-19 drug associated APIs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the COVID-19 drug associated APIs industry?

For detailed insights on the mergers and acquisitions in the COVID-19 drug associated APIs industry, request a sample here.

What are the key dynamics influencing the COVID-19 drug associated APIs market growth? SWOT analysis of the COVID-19 drug associated APIs market.

For detailed insights on the key dynamics influencing the COVID-19 drug associated APIs market growth and SWOT analysis of the COVID-19 drug associated APIs industry, request a sample here.